Ruxolitinib for symptom control in certain blood cancer types
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 2 study tests ruxolitinib (a targeted medicine) in people with essential thrombocythemia or polycythemia vera who still have troublesome symptoms. It aims to see whether it can reduce symptoms by changing disease activity and blood-related inflammation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with essential thrombocythemia or polycythemia vera based on 2016 criteria
- Your risk category must be “lower risk” (not the study’s high-risk group) for your diagnosis
- You have significant symptoms on a questionnaire score (MPN-SAF TSS/MPN-10): the total must be over 10 and at least one symptom area over 5
- You are 18 or older, and you can do daily activities at a limited level (ECOG 2 or less)
- Your blood counts and organ tests (kidneys, liver, etc.) must meet specific lab thresholds
- You can’t be taking certain drug types that strongly interact with ruxolitinib, and you must use proper pregnancy prevention if applicable
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study compares ruxolitinib against hydroxycarbamide or interferon as the first treatment for people with high-risk polycythemia vera. It aims to see which option works better to reduce disease-related problems and complications.
This Phase 2 trial tests a combination of pegylated interferon and ruxolitinib in adults with polycythemia vera who can’t tolerate hydroxyurea or don’t respond well to it. If you qualify, it may help control blood counts and disease symptoms when standard treatment hasn’t worked.
This Phase 2 study tests ruxolitinib, a targeted medicine, to improve outcomes in T-cell large granular lymphocytic leukemia (T-LGLL). It is for people whose disease is causing symptoms or who have already tried other treatment, with specific blood, infection, and medication requirements.
This trial tests a new combination of two drugs, ruxolitinib and ulixertinib, for people with myelofibrosis whose disease is not fully controlled by ruxolitinib alone. The goal is to see if adding ulixertinib can improve spleen enlargement, symptoms, or bone marrow changes.
This trial studies ruxolitinib, a medicine that affects immune signaling, in people whose T-cell or NK-cell lymphoma has returned or hasn’t responded to treatment. It may help shrink lymphoma and improve symptoms after other therapies.
This Phase 1 study tests CK0804 (plus T-regs, a type of immune cell approach) for people with myelofibrosis whose disease is not adequately controlled on ruxolitinib. It may help improve blood counts, symptoms, and/or the size of an enlarged spleen.
Hear when a new Essential Thrombocythemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.